Alterity Therapeutics Limited
ATHE
3.91 EUR
1 Tag: N/A
Der Alarm wird direkt gespeichert, ohne auf die Homepage zu springen.
Kursalarme fuer ATHE
Bitte anmelden, um Kursalarme zu sehen und zu speichern.
Finanzen
Unternehmensinfo
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Aktuelle News
-
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
Vorschau anzeigen
– Newly granted patent extends protection for ATH434 to at least 2045, significantly enhancing its strategic value and long-term commercial potential – – Strengthens ATH434’s intellectual property portfolio as it advances toward Phase 3 development in Multiple System Atrophy – – Enables future development of ATH434 for Parkinson’s disease and other major neurodegenerative disorders – MELBOURNE, Australia and SAN FRANCISCO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ
-
Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference
Vorschau anzeigen
MELBOURNE, Australia and SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will present at the 46th Annual Canaccord Genuity Growth Conference on Tuesday, August 11, 2026 at 1:30 p.m. ET in the United States. A link to the live and archived webcas
-
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
Vorschau anzeigen
Highlights FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSAPivotal Phase 3 trial activities on track to initiate by year-end 2026Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder valuePeer-reviewed publicatio
-
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
Vorschau anzeigen
– Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol — – FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA – – Pivotal Phase 3 trial activities on track to initiate by year-end 2026 – MELBOURNE, Australia and SAN FRANCISCO, July 07, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” o
-
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
Vorschau anzeigen
– Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, and treatment duration – – FDA agrees on UMSARS Part I as primary endpoint after ATH434 demonstrated 48% slowing of disease progression versus placebo in Phase 2 study – – FDA agrees with 50mg dose level which achieved clinically and statistically significant efficacy in Phase 2 study – – Pivotal Phase 3 trial activities on track to initiate by year-en